Relapsing multiple sclerosis

18 trials 6 recruiting MedDRA PT
18 Registered trials
6 Recruiting
9 Unique sponsors
10 Unique IMPs
17 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 8
— ATC code not specified 10
H Endocrinology (ATC H) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
BTK inhibitor 2 substances
Monoclonal antibody (chimeric) 1 substance
Corticosteroid 1 substance
CAR-T cell therapy 1 substance
Phase III: 11 Phase II/III: 1 Phase II: 3 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

11 trials
  • Immunic AG Commercial
    VIDOFLUDIMUS CALCIUM
    2024-514618-11-00 4 countries 2022 n=314
    Ended
  • Immunic AG Commercial
    VIDOFLUDIMUS CALCIUM
    2024-514619-88-00 4 countries 2022 n=339
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2023-509275-17-00 10 countries 2025 n=215
    Recruiting
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2023-509345-12-00 13 countries 2022 n=464
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2023-509372-41-00 15 countries 2022 n=563
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-01 23 countries 2024 n=1,405
    Recruiting
  • Sanofi-Aventis Research & Development Commercial
    TERIFLUNOMIDE; TOLEBRUTINIB
    2023-503631-18-00 2 countries n=75
    Not authorised
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2024-516680-91-00 2 countries 2020 n=137
    Ended
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2024-519284-18-00 1 country 2025 n=233
    Recruiting
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2025-521127-73-00 4 countries 2025 n=84
    Ended
  • Region Stockholm – SLSO Academic
    TOLEBRUTINIB
    2025-523892-50-00 1 country n=60
    Pending

Phase II/III

1 trial
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2025-522257-19-00 2 countries 2026 n=48
    Recruiting

Phase II

3 trials
  • Biogen Idec Research Limited Commercial
    (R)-1-(TERT-BUTYL)-N-(8-(2-((1-METHYL-1H-PYRAZOL-4-YL)AMINO)PYRIMIDIN-4-YL)-2-(OXETAN-3-YL)-2,3,4,5-TETRAHYDRO-1H-BENZO[C]AZEPIN-5-YL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE; DIROXIMEL FUMARATE; GADOTERIC ACID; METHYLPREDNISOLONE
    2022-502552-31-00 7 countries 2023 n=225
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2022-502619-13-00 3 countries 2022 n=67
    Ended
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2025-523757-33-00 1 country 2026 n=120
    Recruiting

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2024-512714-18-00 4 countries 2025 n=15
    Recruiting

Phase I

1 trial
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2023-509555-13-00 1 country 2024 n=164
    Ended

Phase I (Other)

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2023-507820-22-00 4 countries 2024 n=56
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Tg Therapeutics Inc. Commercial 6 Phase I, Phase II/III, Phase II, Phase III 3
Novartis Pharma AG Commercial 4 Phase III, Phase I/II 2
Immunic AG Commercial 2 Phase III 0
Celgene Corp. Commercial 1 Phase I (Other) 0
Biogen Idec Research Limited Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
Sanofi-Aventis Research & Development Commercial 1 Phase III 0
Region Stockholm – SLSO Academic 1 Phase III 0
New trials by year
2020
1
2022
5
2023
1
2024
3
2025
4
2026
2
← All indication landscapes